Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.

ABSTRACT:

Background and objectives

The effectiveness and tolerability of tapentadol extended release (ER), a centrally acting analgesic with μ-opioid receptor agonist and norepinephrine (noradrenaline) reuptake inhibitor activities, have been demonstrated in patients with chronic pain, including those switching directly from prior opioid therapy. The objective of the current study was to evaluate the effectiveness and safety of conversion to oral tapentadol ER (50-250 mg twice daily) from previous around-the-clock strong opioid therapy in patients with moderate to severe, chronic malignant tumor-related cancer pain that was well-controlled.

Methods

This randomized, open-label, phase III study, which was conducted in Japan, included a 1- to 2-week screening period (on previous opioid)

SUBMITTER: Imanaka K 

PROVIDER: S-EPMC4062813 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature